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To the Editor: Glucose uptake into muscle and fat is im-
paired in insulin-resistant states [1]. In response to insulin,
vesicles containing GLUT4 are redistributed from the cell
interior to the plasma membrane where they dock and fuse
with the plasma membrane (GLUT4 translocation), en-
abling glucose uptake [2]. In vitro studies suggest that Tre-2
BUB2 CDC16, 1 domain family member 4 (TBC1D4),
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which is also known as Akt substrate of 160 kDa (AS160),
plays an important role in GLUT4 translocation [3] making
TBC1D4 an excellent candidate gene for insulin resistance.
We have assembled a cohort of patients with severe
insulin resistance (SIR) (diagnosed on the basis of a fasting
insulin of >150 pmol/l and/or a postprandial insulin of
>1500 pmol/l and/or the presence of acanthosis nigricans
or, if diabetic, a requirement of >200 U insulin daily) likely
to be enriched for monogenic causes of the condition. All
participants provided informed consent following approval
by our local ethics committee. We recently reported a novel
pathogenic mutation in TBC1D4 (R363X) which impaired
GLUT4 translocation [4]. It is associated with an unusual
insulin-resistance phenotype characterised by normal fast-
ing insulin and glucose levels with elevated postprandial
glucose and a disproportionate rise in insulin following
glucose ingestion [4]. In the fasting state, low circulating
insulin levels predominantly regulate hepatic glucose
production. After a glucose challenge, insulin levels rise,
suppressing hepatic glucose production and promoting
glucose uptake in muscle and fat, suggesting that this
phenotype may be indicative of peripheral insulin resistance
with preserved hepatic insulin sensitivity [4]. In order to
investigate whether mutations in TBC1D4 contribute more
widely to SIR, we sequenced the coding regions of
TBC1D4 (21 exons, 3894 nucleotides) in 156 patients from
the cohort. Here we describe three additional novel non-
synonymous TBC1D4 variants.
An N1206S variant (c.3617 G>A) results in the sub-
stitution of an asparagine residue (conserved from humans
to zebrafish) with serine. This heterozygous variant,
predicted to be ‘probably damaging’ by PolyPhen [5] and
‘deleterious’ by SIFT [6], was found in two patients. The
first patient presented at age 16 years with weight gain
(BMI 28.5 kg/m2, BMI SD score +2.1 kg/m2, acanthosis
nigricans and normal fasting glucose and insulin levels; see
Electronic supplementary material [ESM] Table 1). During
an OGTT she had impaired glucose tolerance with a dra-
matic rise in insulin (ratio of peak to fasting insulin=90,
mean ratio in BMI-matched controls in the Ely study 8.5)
[7]. Her mother (BMI 25 kg/m2, BMI SD score +1 kg/m2),
the only accessible family member with the variant, was
normoglycaemic but had a modestly elevated peak-to-
fasting-insulin ratio of 10.5 (ESM Table 1) suggesting that
this variant alone could not fully account for the proband’s
phenotype. The second SIR patient with this variant was a
woman with poorly controlled type 2 diabetes mellitus
despite administration of nearly 200 U insulin. It was not
possible to assess her family members.
The N1206S variant was present in 1.6% of 200
ethnically matched healthy controls so we went on to
evaluate its effect in three separate population studies with
OGTT data. The Ely study is a population-based study
comprising 1,669 participants [7]. The Botnia study is a
prospective study of 2,770 Finns followed up for a median
period of 23.5 years [8]. The third population was a cohort
of 524 unrelated morbidly obese Italians (mean BMI of
41 kg/m2) recruited from the Department of Clinical
Sciences, University of Rome, Rome, Italy [9]. Our
hypothesis was that N1206S carriers would have elevated
2 h glucose levels and a disproportionate rise in insulin post
OGTT, as judged by higher ratios of insulin at 60 and
120 min to fasting insulin. The combined minor allele
frequency was 1.2% in the three populations. Pooled esti-
mates from inverse-variance fixed-effects meta-analyses of
4468 individuals across the three studies (Table 1) indicate
that individuals with the N1206S variant have higher
120 min blood glucose levels (p=0.021) and ratios of 60
and 120 min to fasting insulin (p=0.006 and p=0.024, re-
spectively). There were no significant differences in fasting
glucose and insulin levels. This suggests that participants
with the N1206S variant may have a small but significant
impairment in peripheral insulin sensitivity with preserved
hepatic insulin sensitivity. There was no statistically
significant heterogeneity between the studies. In an effort
to characterise the effects of this variant on GLUT4
translocation, we transiently transfected 3T3L1 adipocytes
with wild-type or N1206S TBCID4 cDNA vectors as
described previously [4], but were unable to demonstrate
any differences in GLUT4 translocation (ESM Fig. 1). This
may reflect the apparently subtle effects of this mutant in
vivo or a lack of sensitivity of the in vitro assay.
A heterozygous N655Y variant (c. 1964T>A; PolyPhen
prediction: ‘probably damaging’; SIFT prediction: ‘delete-
rious’) [5, 6] causes the substitution of an asparagine
residue (conserved in a range of species from humans to
mice) with tyrosine at amino acid number 655. It was found
in a SIR patient with morbid obesity since childhood and
was absent in 200 ethnically matched controls. The proband
also has a pathogenic Y221C mutation in the beta
melanocyte-stimulating hormone (βMSH) region of the
POMC gene, which is likely to contribute to her obesity
(current BMI 45 kg/m2, BMI SD score +3.9 kg/m2) (POMC
encodes pro-opiomelanocortin) [10]. She was normogly-
caemic with elevated fasting and postprandial insulin levels
compared with sex- and BMI-matched controls from the
Ely study (ESM Table 1) [7]. Her mother (BMI 34 kg/m2,
BMI SD score +2.7 kg/m2) was the only accessible family
member. She too had the N655Y TBC1D4 and the Y221C
POMC variant. Although her fasting and postprandial
insulin levels, in isolation, were compatible with her BMI,
she had an elevated peak-to-fasting-insulin ratio of 13
(ESM Table 1). Although the proband’s severe insulin
resistance can be explained by her morbid obesity, it is
possible that the N655Y variant might also be contributing
to her phenotype. However, the variant had no effects on
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GLUT4 translocation in transfected 3T3L1 adipocytes
(ESM Fig. 1).
An N785K variant (c. 2355 G>C; PolyPhen prediction:
‘benign’; SIFT prediction: ‘tolerated’) [5, 6] was identified
in two SIR patients of Pakistani origin. This variant
causes the substitution of a non-conserved asparagine
residue with lysine at amino acid number 785. It was
present in one out of 192 ethnically matched control
alleles. The first patient (BMI 24.1 kg/m2, BMI SD
score +1.58 kg/m2, aged 15) with the variant was a young
man diagnosed with diabetes at the age of 3 years who
had poor glycaemic control despite being on almost
200 U insulin per day and metformin. The other patient
presented with acanthosis nigricans during puberty fol-
lowing a period of weight gain. She had a BMI of
33.5 kg/m2 (BMI SD score 2.9 kg/m2) at the age of 16
with normoglycaemia and elevated fasting and postpran-
dial insulin levels adjusted for BMI (ESM Table 1) [7].
Both probands and their families declined further assess-
ment. This variant was not studied in vitro.
In summary, we have described three novel non-
synonymous variants in TBC1D4. One of these, the
N1206S polymorphism, is associated with higher 2 h
glucose levels and a greater postprandial rise in insulin,
which might be indicative of isolated peripheral insulin
resistance. However, we acknowledge that the effect size is
small and that further follow-up studies are needed to con-
firm this. Because of the lack of adequate co-segregation
data, it was not possible to convincingly establish a
pathogenic role for the N655Y and N785K variants.
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